BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.16% | 59.42% | -61.10% | -164.50% | 33.20% |
| Total Depreciation and Amortization | -21.62% | -1.33% | 0.00% | -1.32% | -1.30% |
| Total Amortization of Deferred Charges | 7.04% | 6.59% | 11.96% | 12.29% | 57.66% |
| Total Other Non-Cash Items | 85.40% | -153.31% | 253.17% | 202.95% | 51.85% |
| Change in Net Operating Assets | -72.06% | 402.76% | -166.36% | 251.93% | -148.06% |
| Cash from Operations | 16.90% | 24.36% | -49.40% | -4.42% | 18.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 47.48% | -84.93% | 27,210.00% | -99.00% | 100.06% |
| Repurchase of Common Stock | -- | 100.00% | -- | 100.00% | 97.83% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -37.39% | 83.24% | -22,766.67% | 99.63% | -348.60% |
| Cash from Financing | -95.89% | -84.95% | 27,295.62% | -98.96% | 208.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.20% | -145.68% | 250.71% | -1,173.17% | 111.00% |